Glaucoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glaucoma – Pipeline Review, H2 2017’, provides an overview of the Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Glaucoma

The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects

The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Glaucoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glaucoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AC Immune SA

Advanced Refractive Technologies Inc

Aerie Pharmaceuticals Inc

Alcon Laboratories Inc

Allergan Plc

Altacor Ltd

Amarantus Bioscience Holdings Inc

Amgen Inc

Annexon Inc

Astellas Pharma Inc

Bausch & Lomb Inc

BioAxone BioSciences Inc

Bionure Farma SL

Can-Fite BioPharma Ltd

Chong Kun Dang Pharmaceutical Corp

Clearside BioMedical Inc

D. Western Therapeutics Institute Inc

Dompe Farmaceutici SpA

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

Fortress Biotech Inc

Gene Signal International SA

Gilead Sciences Inc

Glaukos Corp

Graybug Vision Inc

Han Wha Pharma Co Ltd

Handok Inc

HitGen LTD

Icon Bioscience Inc

ID Pharma Co Ltd

InMed Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Isarna Therapeutics GmbH

Kukje Pharmaceutical Industry Co Ltd

Laboratoires Thea SA

Laboratorios SALVAT SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

Mimetogen Pharmaceuticals Inc

Nemus Bioscience Inc

Neurim Pharmaceuticals Ltd

NicOx SA

NoNO Inc

Novaliq GmbH

Ocular Therapeutix Inc

Oculis ehf

Ohr Pharmaceutical Inc

Pivot Pharmaceuticals Inc

Profarma

Q BioMed Inc

Quark Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Glaucoma - Overview 6

Glaucoma - Therapeutics Development 7

Glaucoma - Therapeutics Assessment 22

Glaucoma - Companies Involved in Therapeutics Development 34

Glaucoma - Drug Profiles 59

Glaucoma - Dormant Projects 259

Glaucoma - Discontinued Products 264

Glaucoma - Product Development Milestones 266

Appendix 276

List of Tables

List of Tables

Number of Products under Development for Glaucoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Glaucoma – Pipeline by AC Immune SA, H2 2017

Glaucoma – Pipeline by Advanced Refractive Technologies Inc, H2 2017

Glaucoma – Pipeline by Aerie Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Alcon Laboratories Inc, H2 2017

Glaucoma – Pipeline by Allergan Plc, H2 2017

Glaucoma – Pipeline by Altacor Ltd, H2 2017

Glaucoma – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Glaucoma – Pipeline by Amgen Inc, H2 2017

Glaucoma – Pipeline by Annexon Inc, H2 2017

Glaucoma – Pipeline by Astellas Pharma Inc, H2 2017

Glaucoma – Pipeline by Bausch & Lomb Inc, H2 2017

Glaucoma – Pipeline by BioAxone BioSciences Inc, H2 2017

Glaucoma – Pipeline by Bionure Farma SL, H2 2017

Glaucoma – Pipeline by Can-Fite BioPharma Ltd, H2 2017

Glaucoma – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Glaucoma – Pipeline by Clearside BioMedical Inc, H2 2017

Glaucoma – Pipeline by D. Western Therapeutics Institute Inc, H2 2017

Glaucoma – Pipeline by Dompe Farmaceutici SpA, H2 2017

Glaucoma – Pipeline by Elsalys Biotech SAS, H2 2017

Glaucoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Glaucoma – Pipeline by Fortress Biotech Inc, H2 2017

Glaucoma – Pipeline by Gene Signal International SA, H2 2017

Glaucoma – Pipeline by Gilead Sciences Inc, H2 2017

Glaucoma – Pipeline by Glaukos Corp, H2 2017

Glaucoma – Pipeline by Graybug Vision Inc, H2 2017

Glaucoma – Pipeline by Han Wha Pharma Co Ltd, H2 2017

Glaucoma – Pipeline by Handok Inc, H2 2017

Glaucoma – Pipeline by HitGen LTD, H2 2017

Glaucoma – Pipeline by Icon Bioscience Inc, H2 2017

Glaucoma – Pipeline by ID Pharma Co Ltd, H2 2017

Glaucoma – Pipeline by InMed Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Ironwood Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Isarna Therapeutics GmbH, H2 2017

Glaucoma – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017

Glaucoma – Pipeline by Laboratoires Thea SA, H2 2017

Glaucoma – Pipeline by Laboratorios SALVAT SA, H2 2017

Glaucoma – Pipeline by Laboratorios Sophia SA de CV, H2 2017

Glaucoma – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Glaucoma – Pipeline by Mimetogen Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Nemus Bioscience Inc, H2 2017

Glaucoma – Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Glaucoma – Pipeline by NicOx SA, H2 2017

Glaucoma – Pipeline by NoNO Inc, H2 2017

Glaucoma – Pipeline by Novaliq GmbH, H2 2017

Glaucoma – Pipeline by Ocular Therapeutix Inc, H2 2017

Glaucoma – Pipeline by Oculis ehf, H2 2017

Glaucoma – Pipeline by Ohr Pharmaceutical Inc, H2 2017

Glaucoma – Pipeline by Pivot Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Profarma, H2 2017

Glaucoma – Pipeline by Q BioMed Inc, H2 2017

Glaucoma – Pipeline by Quark Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Glaucoma – Pipeline by Santen Pharmaceutical Co Ltd, H2 2017

Glaucoma – Pipeline by Senju Pharmaceutical Co Ltd, H2 2017

Glaucoma – Pipeline by Shire Plc, H2 2017

Glaucoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Glaucoma – Pipeline by Sylentis SAU, H2 2017

Glaucoma – Dormant Projects, H2 2017

Glaucoma – Dormant Projects, H2 2017 (Contd..1), H2 2017

Glaucoma – Dormant Projects, H2 2017 (Contd..2), H2 2017

Glaucoma – Dormant Projects, H2 2017 (Contd..3), H2 2017

Glaucoma – Dormant Projects, H2 2017 (Contd..4), H2 2017

Glaucoma – Discontinued Products, H2 2017

Glaucoma – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Glaucoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports